A randomized, placebo‐controlled, dose‐escalation phase I/II multicenter trial of low‐dose cidofovir for BK polyomavirus nephropathy
These preliminary results indicate that low-dose cidofovir was safe and tolerated but had no significant BKPyV-specific antiviral effect in KTRs with BKPyVAN.
Authors
- Michelle A. Josephson (ORCID: https://orcid.org/0000-0003-3426-0794)
- Clifton E. Kew
- Richard J. Whitley (ORCID: https://orcid.org/0000-0001-9959-9276)
- Hannah Imlay (ORCID: https://orcid.org/0000-0002-3429-4655)
- Ajit P. Limaye (ORCID: https://orcid.org/0000-0002-5350-9025)
- Deborah Adey (ORCID: https://orcid.org/0000-0001-9090-9135)
- Milagros Samaniego (ORCID: https://orcid.org/0000-0001-7914-1663)
- Jo‐Anne H. Young (ORCID: https://orcid.org/0000-0003-4182-341X)
- Alexander C. Wiseman (ORCID: https://orcid.org/0000-0002-8619-0938)
- James Rooney (ORCID: https://orcid.org/0000-0001-9986-0307)
- V. Ram Peddi
- John W. Gnann
Institutions
- University of Minnesota (US)
- University of Wisconsin–Madison (US)
- Medical University of South Carolina (US)
- University of California, San Francisco (US)
- University of Washington (US)
- University of Utah (US)
- California Pacific Medical Center (US)
- Denver Health Medical Center (US)
- University Medical Center (US)
- University of Alabama at Birmingham (US)
- University of Chicago (US)
- University of Colorado Health (US)
- Gilead Sciences (United States) (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Transplant Infectious Disease
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1111/tid.14367
- Citations
- 4
- Primary Topic
- Polyomavirus and related diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Gilead Sciences
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases